Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL

Current Opinion in Immunology

Volumn 8, Issue 5, 1996, Pages 674-680

  Nash, Richard A ^a   Storb, Rainer ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENEIC RESTRICTION; CELL TRANSPLANTATION; DEVELOPMENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; SHORT SURVEY; STEM CELL TRANSPLANTATION;

EID: 0030271765     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(96)80085-9     Document Type: Article

References (64)

1. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 62:1967;21-78.
2. Sprent J, Korngold R, Thomas Ed. Murine models for graft-versus-host disease. Forman SJ, blume Kg. Bone Marrow Transplantation. 1994;220-230 Blackwell Scientific Publications, Boston.
3. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, Lerner KG, Glucksberg H, Buckner CD. Bone-marrow transplantation. N Engl J Med. 292:1975;832-843.
4. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, Lerner Kg, Glucksberg H, Buckner CD. Bone-marrow transplantation. N Engl J Med. 292:1975;895-902.
5. Nash RA, Pepe MS, Storb R, Longton g, Pettinger M, Anasetti C, Appelbaum FR, Bowden R, Deeg HJ, Doney K, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 80:1992;1838-1845.
6. Beatty Pg, Clift RA, Mickelsen EM, Nisperos B, Floumoy N, Martin PJ, Sanders Je, Stewart P, Buckner CD, Storb R, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 313:1985;765-771.
7. Sullivan KM, Agura E, Anasetti C, Appelbaum FR, Badger C, Beaman S, Erickson K, Flowers M, Hansen Ja, Loughran T, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 28:1991;250-259.
8. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 300:1979;1068-1073.
9. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. Seattle Marrow Transplant Team N Engl J Med. 304:1981;1529-1533.
10. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hamatologic neoplasms. N Engl J Med. 320:1989;828-834.
11. Kolb HJ, Mittemuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 76:1990;2462-2465.
12. Norton J, al-Saffar N, Sloan JP. An immunohistological study of gamma/delta lymphocytes in human cutaneous graft-versus-host disease. Bone Marrow Transplant. 7:1991;205-208.
13. Norton J, al-Saffar N, Sloane JP. Immunohistological study of distribution of gamma/delta lymphocytes after allogeneic bone marrow transplantation. J Clin Pathol. 45:1992;1027-1028.
14. Viale M, Ferrini S, Bacigalupo A. TCR gamma/delta positive lymphocytes after allogeneic bone marrow transplantation. Bone Marrow Transplant. 10:1992;249-253.
15. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Berrett TA, Bluestone JA, Vallera DA. Lethal murine graft-versus-host disease induced by donor γ/δ expressing T cells with specificity for host nonclassical major histocompatibility complex class lb antigens. Blood. 87:1996;827-837.
16. Ellison CA, MacDonald GC, Rector ES, Gartner JG. γδ T cells in the pathobiology of murine acute graft-versus-host disease. J Immunol. 155:1995;4189-4198.
17. Shresta S, MacIvor DM, Heusel JW, Russell JH, Ley TJ. Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells. Proc Natl Acad Sci USA. 92:1995;5679-5683.
18. + cytotoxic T lymphocytes.
19. Blazar BR, Taylor PA, Linsley PS, Vallera DA. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood. 83:1994;3815-3825.
20. Wallace PM, Johnson JS, Macmaster JF, Kennedy KA, Gladstone P, Linsley PS. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplatation. 58:1994;602-610.
21. of special interest Schlegel Pg, Vaysburd M, Chen Y, Butcher EC, Chao NJ. Inhibition of T cell constimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers. J Immunol. 155:1995;3856-3856 In mice, another T cell costimulatory pathway was identified which might be targeted to modulate or prevent the development of clinical GVHD. mAbs specific for VCAM-1 but not VLA-4 reduced the lethality of GVHD in mice after transplant.
22. of special interest Tanaka T, Ohtsuka Y, Yagita H, Shiratori Y, Omata M, Okumura K. Involvement of α1 and α4 integrins in gut mucosal injury of graft-versus-host disease. Int Immunol. 7:1995;1183-1189 The α1 and α4 integrins may have a role in the development of intestinal GVHD in mice. mAbs specific for α1 and α4 integrins prevented intestinal GVHD in mice after transplant.
23. Krenger W, Ferrara JLM. Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res. 15:1996;50-73.
24. Ushiyama C, Hirano T, Miyajima H, Okumura K, Ovary Z, Hashimoto H. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. J Immunol. 154:1995;2687-2696.
25. Storb R, Epstein RB, Ragde H, Bryant J, Thomas ED. Marrow engraftment by allogeneic leukocytes in lethally irradiated dogs. Blood. 30:1967;805-811.
26. Storb R, Epstein RB, Ragde H, Bryant J, Thomas ED. Marrow grafts by combined marrow and leukocyte infusions in unrelated dogs selected by histocompatibility typing. Transplantation. 6:1968;587-593.
27. Storb R, Graham TC, Epstein RB, Sale GE, Thomas ED. Demonstration of hemopoietic stem cells in the peripheral blood of baboons by cross circulation. Blood. 50:1977;537-542.
28. of special interest Pan L, Delmonte J Jr, Jalonen CK, Ferrara -JLM. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 86:1995;4422-4429 G-CSF has immunomodulatory effects which, when used as pretreatment on donor mice, will reduce the incidence of GVHD.
29. of special interest Sandmaier BM, Storb R, Santos EB, Krizanac-Bengez L, Lian T, McSweeney PA, Yu C, Schuening FG, Deeg HJ, Graham T. Allogeneic transplants of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors. Blood. 87:1996;3508-3513 `Mobilized' PBSC transplants in dogs resulted in rapid sustained engraftment even in MHC-mismatched transplants. The incidence and severity of acute GVHD were not different than previously reported for nonmobilized PBSCs or marrow.
30. Diamond DJ, Chang KL, Jenkins KA, Forman SJ. Immunohistochemical analysis of T cell phenotypes in patients with graft-versus-host disease following allogeneic bone marrow transplantation. Transplantation. 59:1995;1436-1444.
31. Kubo K, Yamanaka K, Kiyoi H, Fukutani H, Ito M, Hayakawa R, Ohno R, Naoe T. Different T-cell receptor repertoires between lesions and peripheral blood in acute graft-versus-host disease after allogeneic bone marrow transportation. Blood. 87:1996;3019-3026.
32. Petersdorf EW, Longton GM, Anasetti C, Martin PJ, Mickelson EM, Smith AG, Hansen JA. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood. 86:1995;1606-1613.
33. Davies SM, Shu XO, Blazar BR, Filipovich AH, Kersey JH, Krivit W, McCullough J, Miller WJ, Ramsay NKC, Segall M, et al. Unrelated donor bone marrow transplantation: influence of HLA A and B incompatibility on outcome. Blood. 86:1995;1636-1642.
34. Balduzzi A, Gooley T, Anasetti C, Sanders JE, Martin PJ, Petersdorf EW, Appelbaum FR, Buckner CD, Matthews D, Storb R, et al. Unrelated donor marrow transplantation in children. Blood. 86:1995;3247-3256.
35. of outstanding interest den Haan JMM, Sherman NE, Blokland E, Huczko E, Koning F, Wouter Drijfhout J, Skipper J, Shabanowitz J, Hunt DF, Engelhard VH, Goulmy E. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science. 268:1995;1476-1480 See annotation [37].
36. of outstanding interest Wang W, Meadows LR, den Haan JMM, Sherman NE, Chen Y, Blokland E, Shabanowitz J, Agulnik AI, Hendrickson RC, Bishop CE, et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science. 269:1995;1588-1590 See annotation [37].
37. of outstanding interest Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JHF, Vossen JJ. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 334:1996;281-285 Along with [35,36], this paper documents the identification of the peptide sequence of two mHCs and the demonstration of an association of GVHD with mHCs, both of which are exciting developments and will allow for further development of GVL strategies.
38. of special interest Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, Storb R, Buckner CD. Transplantation of allogeneic peripheral blood stem cell mobilized by recombinant human granulocyte colony-stimulating factor. Blood. 85:1995;1655-1658 See annotation [40].
39. of special interest Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Löffler H, Hunter A, Russell NH. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by Filgrastim (granulocyte colony-stimulating factor). Blood. 85:1995;1666-1672 See annotation [40].
40. dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 86:1995;2842-2848 The first reports of Phase II studies of allogenic PBSC transplantation [38-40]. Phase III studies are in progress but allogeneic PBSC transplantation appears promising.
41. Gratwohl A, Hermans J, apperley J, Arcese W, Bacigalupo A, Bandini G, di Bartolomeo P, Boogaerts M, Bosi A, Carreras E, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Blood. 86:1995;813-818.
42. of special interest Przepiorka D, Weisdorf D, Martin P, Klingemann H-G, Beatty P, Hows J, Thomas ED. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 15:1995;825-828 A report on a consensus conference at which it was agreed that persistent nausea with histological evidence of GVHD but no diarrhea be included as stage I gastrointestinal GVHD. Recommendations were made for the publishing of results of GVHD prevention trials.
43. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 314:1986;729-735.
44. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Hansen J, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood. 68:1986;119-125.
45. Storb R, Pepe M, Anasetti C, Appelbaum FR, Beatty P, Doney K, Martin P, Stewart P, Sullivan KM, Witherspoon R, et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood. 76:1990;1037-1045.
46. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med. 329:1993;1225-1230.
47. of special interest Nash RA, Etzioni R, Storb R, Furlong T, Gooley T, Anasetti C, Appelbaum FR, Doney K, Martin P, Slattery J, et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood. 85:1995;3746-3753 See annotation [48].
48. of special interest Fay JW, Wingard JR, Antin JH, Collins RH, Pineiro LA, Blazar BR, Saral R, Bierer BE, Przepiorka D, Fitzsimmons WE, et al. FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transporation. Blood. 87:1996;3514-3519 References [47,48] represent the first reports of the use of tacrolimus (FK506) for the prevention of acute GVHD.
49. Holler E, Kolb HJ, Mittemüller J, Kaul M, Ledderose G, Duell T, Seeber B, Schleuning M, Hintemeier-Knabe R, Ertl B, et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNFα) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFα (MAK 195F). Blood. 86:1995;890-899.
50. Anasetti C, Lin A, Nademanee A, Gluckman E, Messner H, Beatty P, Chauncey T, Jacobsen N, Chao N, Powles R, et al. A Phase II/III randomized, double-blind, placebo-controlled multicenter trial of humanized anti-TAC for prevention of acute graft-versus-host disease (GVHD) in recipients of marrow transplants from unrelated donors [abstract]. Blood. 86:1995;621. (suppl).
51. McGlave P, Bartsch G, Anasetti C, Ash R, Beatty P, Gajewski J, Kernan NA. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood. 81:1993;543-550.
52. Spencer A, Szydlo RM, Brookes PA, Kaminski E, Rule S, Vanrhee F, Ward KN, Hale G, Waldmann H, Hows JM, et al. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion major prognostic implact of HLA class I identity between donor and recipient. Blood. 86:1995;3590-3597.
53. Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F, et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood. 83:1994;1980-1987.
54. Martin PJ, Schoch G, Fisher L, Byers V, Ansetti C, Appelbaum FR, Beatty PG, Doney K, McDonald GB, Sanders JE, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 76:1990;1464-1472.
55. Martin PJ, Schoch G, Fisher L, Byers V, Appelbaum FR, McDonald GB, Storb R, Hansen JA. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood. 77:1991;1821-1828.
56. Cahn JY, Bordigoni P, Tiberghien P, Milpied N, Brion A, Widjenes J, Lioure B, Michel G, Burdach S, Kolb H-J, et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. Transplantation. 60:1995;939-942.
57. Martin PJ, Nelson BJ, Appelbaum FR, Anasetti C, Deeg HJ, Hansen JA, McDonald GB, Nash RA, Sullivan KM, Witherspoon RP, et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood. 1996;. in press.
58. Heslop HE, Benaim E, Brenner MK, Krance RA, Stricklin LM, Rochester RJ, Billing R. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet. 346:1995;805-806.
59. of special interest Parker PM, Chao N, Nademanee A, O'Donnell Mr, Schmidt GM, Snyder DS, Stein AS, Smith EP, Molina A, Stepan DE, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood. 86:1995;3604-3609 A report on another potentially valuable agent for the treatment of chronic GVHD.
60. of special interest Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, et al. Graft-versus-leukemia effect of donor transfusions in marrow grafted patients. Blood. 86:1995;2041-2050 An important report expanding the experience of donor lymphocyte infusions for CML patients in relapse and now including patients with acute myeloid leukemia, acute lymphocytic leukemia and myelodysplastic syndrome in relapse after transplant.
61. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood. 87:1996;1196-1198.
62. of special interest Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-host leukemia responses from graft-versus-host disease. Blood. 86:1995;1261-1268 Documents the association between the cell dose of the donor lymphocyte infusion and the induction of remission and GVHD.
63. Robinson N, Sanders JE, Benyunes MC, Beach K, Lindgren C, Thompson JA, Appelbaum FR, Fefer A. Phase 1 trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood. 87:1996;1249-1254.
64. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 87:1996;2195-2204.